Compare IMMP & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | DFLI |
|---|---|---|
| Founded | 1987 | 2020 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 49.0M |
| IPO Year | 2012 | N/A |
| Metric | IMMP | DFLI |
|---|---|---|
| Price | $0.62 | $2.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.50 | $3.25 |
| AVG Volume (30 Days) | ★ 22.9M | 339.3K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $445.09 | N/A |
| Revenue Next Year | N/A | $51.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.15 |
| 52 Week High | $3.53 | $5.15 |
| Indicator | IMMP | DFLI |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 45.87 |
| Support Level | $0.29 | $1.56 |
| Resistance Level | $1.89 | $2.28 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 42.48 | 68.85 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.